title: Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus.
abstract: OBJECTIVE
  To investigate changes in urinary PGE(2) after ibuprofen treatment in preterm infants with patent ductus arteriosus (PDA).
  
  
  METHODS
  Twenty preterm infants with a hemodynamically significant PDA (gestational age, 28.6 +/- 2.3 weeks) and 20 controls (gestational age, 30.4 +/- 1.5 weeks) were prospectively enrolled at 48-72 h of life. After enrollment, the former underwent conventional ibuprofen-lysine treatment. At 48-72 h (T(0)) and 108-144 h of life (T(1)), urine samples were noninvasively collected in both groups to measure urinary PGE(2) concentrations (enzyme immunoassay method), and renal function was investigated.
  
  
  RESULTS
  Urinary PGE(2) decreased significantly both in ibuprofen-treated patients (66.95 +/- 16.78 vs. 27.15 +/- 17.92 pg/mL, P < 0.001) and in controls (71.7 +/- 16.2 vs. 53.2 +/- 18.4 pg/mL, P < 0.001) from T(0) to T(1). However, urinary PGE(2) at T(1) was significantly lower (P < 0.001) in the ibuprofen group compared to the control group. Acute renal failure occurred in three ibuprofen-treated patients (15%).
  
  
  CONCLUSIONS
  Ibuprofen markedly reduces (59.4%) urinary PGE(2) and may alter renal function in the newborn.
authors.affiliation: Department of Pediatrics and Clinical Medicine-Section of Neonatal Intensive Care Unit, University of Cagliari, Via Ospedale 119, 09124 Cagliari, Italy. roant@tiscali.it
authors.forename: R
authors.initials: R
authors.lastname: Antonucci
authors.forename: L
authors.initials: L
authors.lastname: Cuzzolin
authors.forename: A
authors.initials: A
authors.lastname: Arceri
authors.forename: A
authors.initials: A
authors.lastname: Dessì
authors.forename: V
authors.initials: V
authors.lastname: Fanos
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D015232:Dinoprostone / Q000652:urine*; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects / Q000627:therapeutic use*; D007231:Infant, Newborn; D007234:Infant, Premature; D007262:Infusions, Intravenous; D008297:Male; D011446:Prospective Studies
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003404:Creatinine; D015232:Dinoprostone; D007052:Ibuprofen